# HVR Cardio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/hvr-cardio

- Industry: Medical Devices & Equipment
- Headquarters: Espoo, Finland
- Website: www.hvrcardio.com/
- Total disclosed funding: $12M
- Latest round: Series B (Jan 12, 2023)
- Investors on record: 2

## About

Founded in 2009 by Olli Keränen (CSO) and based in Espoo, Finland, HVR Cardio Oy is a cardiovascular device company that develops structural heart cardiovascular products for transcatheter mitral valve repair solutions. In January 2023, HVR Cardio Oy raised EUR 10.7 million in Series B funding co-led by Innovestor and Tesi Srl. As of 2023, the company is led by its CEO, Tom Fleming.

The company provides its primary product, CathHELIX®, which is a catheter-based mitral valve repair device that is designed to simplify the mitral valve repair process. CathHELIX® has the potential to mimic the efficacy of surgical repair by reducing the mitral annulus geometry. HVR Cardio uses its patented helix ring technology, which is adaptable to both interventional cardiology and cardiac surgery and is tailored to replicate the geometry of the mitral valve.

In addition, the company offers the MAR®, or HVR Cardio Annuloplasty Ring, designed for surgical mitral valve repair. This helix-based device facilitates easier implantation, enhances the reverse remodelling of the enlarged left ventricle, and keeps future catheter options open.

The organization plans to use the January 2023 funding to accelerate its growth and expand its business operations.

## Funding rounds

- Series B, Jan 12, 2023, $12M — Innovestor, Tesi srl

## Investors

- Innovestor (https://capitalatlas.ai/funds/innovestor) — Series B
- Tesi srl — Series B